Neovacs SA

#Neovacs is a French company focused on the development of #Kinoids #therapeutic #vaccines for the treatment of autoimmune and inflammatory diseases and #cancer

[The Lancet Rheumatology @TheLancetRheum]

NEW RESEARCH: LLDAS (#Lupus low disease activity state) attainment is associated with significant protection against flare and damage accrual in #SLE https://t.co/L7NzIXM005… #LancetRheumatology

[Neovacs SA @Neovacs]

Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study https://t.co/rZLQAfkwxM

[Neovacs SA @Neovacs]

Good News for IFNalpha targeting approaches to halt lupus disease

[Lupus Research @LupusResearch]

The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study.

Read more about this exciting study: https://t.co/z8XttMgIKh
#lupusnews

[Lupus Research @LupusResearch]

What is lupus? Watch as #MacktheMolecule breaks it down.

#whatislupus #lupus #lupusvideo #SLE #autoimmune #breakingthrough #preventlupus #treatlupus #curelupus

[Lupus Research @LupusResearch]

It’s been quite a month! Filled with stories of hope from researchers, advocates and people with lupus. Thank you for all you do to help advance lupus research! With your continued support, we will continue keeping up the momentum all year long! #LupusAwarenessMonth

[Neovacs SA @Neovacs]

#Neovacs announces appointment of Dr. Virginia Pascual https://t.co/qhUC5wGh4r #lupus #clinicalresearch #NewsUpdate

[Neovacs SA @Neovacs]

Le Dr. Virginia Pascual rejoint Neovacs #nomination #clinicalresearch #lupus https://t.co/jGuBXCBCu3

[Neovacs SA @Neovacs]

Neovacs presented its Type 1 diabetes project using IFN-K vaccine @ADA_DiabetesPro scientific session

[Neovacs SA @Neovacs]

#neovacs to present the pre-clinical results of IFNalpha Kinoid to treat Type 1 Diabetes at #ADA2019 https://t.co/qlpa8cI0O9

[Neovacs SA @Neovacs]

Le Journal des Biotechs@: Interview Miguel Sieler, CEO de Neovacs https://t.co/4JK2foNIRE

[Neovacs SA @Neovacs]

Neovacs to attend the 13th International Congress on Systemic Lupus Erythematosus in San Francisco, California, April 5-8 2019
#LupusCongress #Lupus2019 #Lupus #Congress #SanFrancisco

[LA BOURSE ET LA VIE TV ⭐️⭐️ @LaBourseEtLaVie]

Miguel Sieler Directeur Général @Neovacs invité de @DidierTestot @LaBourseEtLaVie "Nous sommes dans le trio de tête des entreprises dans le développement clinique pour le lupus". #Biotech https://t.co/7RyEHUqnm8

[Neovacs SA @Neovacs]

Neovacs’ Investigational Lupus Vaccine Shows Positive Results in Phase 2b Trial https://t.co/9DkUkLVXfr

[Neovacs SA @Neovacs]

Get to Know 15 Awesome Biotechs in Paris https://t.co/7XdfWK23gn

[Neovacs SA @Neovacs]

Réécoutez l’ITW de Miguel Sieler, directeur général de #Neovacs - diffusée en direct sur BFMBusiness le 04/07 à 16h https://t.co/0kPTmfo2bY via @BFMBusiness

[Neovacs SA @Neovacs]

French Lupus Vaccine Ready to Move Into Phase III https://t.co/jraaODBPld

[Neovacs SA @Neovacs]

[VIDEO] Interview de Miguel SIELER, Directeur Général de Néovacs https://t.co/6hXSY56B6i via @Boursier_com

[Neovacs SA @Neovacs]

#Neovacs will hold a Webcast conference call today at 10:00 am CEST, log in via the following link: https://t.co/8QTAfy0Wz0

[Neovacs SA @Neovacs]

#Néovacs tiendra une conférence téléphonique aujourd'hui à https://t.co/M1XFjKJcNo CEST, suivez en direct la présentation via le lien suivant : https://t.co/8QTAfy0Wz0